Does combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provide optimized prognostication of glioblastoma outcome?
Optimal assessment of MGMT status as a prognostic biomarker for patients with newly diagnosed GBM treated with chemoradiation requires determination of both promoter methylation and IHC protein expression.
LPCAT1 correlates with the progression of prostate cancer and could be a new biomarker in diagnosis, prognosis and studying the pathogenesis of prostate cancer.